Bevantolol
 |
|
| Clinical data | |
|---|---|
| AHFS/Drugs.com | International Drug Names |
| Routes of administration |
Oral |
| ATC code | C07AB06 (WHO) |
| Legal status | |
| Legal status |
|
| Identifiers | |
|
Systematic (IUPAC) name: (RS)-[2-(3,4-dimethoxyphenyl)ethyl][2-hydroxy-3-(3-methylphenoxy)propyl]amine
|
|
| CAS Number | 59170-23-9  |
| PubChem (CID) | 2372 |
| DrugBank | DB01295 |
| ChemSpider | 2282 |
| UNII | 34ZXW6ZV21 |
| ChEBI | CHEBI:238698 |
| ChEMBL | CHEMBL314010 |
| Chemical and physical data | |
| Formula | C20H27NO4 |
| Molar mass | 345.43 g/mol |
| 3D model (Jmol) | Interactive image |
| Chirality | Racemic mixture |
|
|
|
|
| (verify) | |
Bevantolol (INN) is a drug that acts as both a beta blocker and a calcium channel blocker.[1]
Overview[edit]
Bevantolol is the beta-1 adrenergic antagonist that has shown efficacy as other beta-blockers for the treatment of angina pectoris, and hypertension. For other interesting additional features, such as the lack of side effects in the form of cold extremities, needs further research. Many new evidence has accumulated in the last three years. All data suggest that bevantolol communicates with the alpha-adrenoceptors.
Bevantolol exhibits affinities for alpha-adrenoceptors. Animal experiments confirm agonist and the antagonist effects on alpha-receptors, and to the antagonist activity of the beta-1 receptor. In addition, bevantolol has electrophysiological effects, including the effects on bradycardia through direct action on the sinus node and class 1 anti-arrhythmic activity. Studies in humans have shown that although bevantolol has a short half-life, can be achieved by a good control of hypertension, once daily dosing.
Side effects and benefits[edit]
Bevantolol has very few side effects; does not cause cooling ekstremiteties and insignificant impact on glomerular filtration rate in patients with the kidney damages . The evidences obtained in people to interact with the alpha-adrenoceptor agonist in the brain does not affect peripheral circulation, like other beta blockers does, and not do increase peripheral vascular resistance, but it decreases. It is suggested that further action can be attributed bevantolol partial agonistic activity on alpha-adrenoceptors.[2]
See also[edit]
References[edit]
- ^ Warltier DC, Gross GJ, Jesmok GJ, Brooks HL, Hardman HF (1980). "Protection of Ischemic Myocardium: Comparison of Effects of Propranolol, Bevantolol and N-Dimethyl Propranolol on Infarct Size Following Coronary Artery Occlusion in Anesthetized Dogs". Cardiology. 66.
- ^ Vaughan Williams E. M. (1987): Bevantolol: a beta-1 adrenoceptor antagonist with unique additional actions. J Clin Pharmacol, 27 (7): 450-460.
 |
This article about an amine is a stub. You can help Wikipedia by expanding it. |
 |
This drug article relating to the cardiovascular system is a stub. You can help Wikipedia by expanding it. |
